News

Xiromed LLC Launches Docetaxel Injection, USP, 10mg/mL

September 27, 2021

Florham Park, NJ, September 27, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™.     Xiromed CEO, Narasimhan Mani commented, “The […]


Xiromed LLC Launches Fluorouracil Injection 50mg/mL

August 12, 2021

Florham Park, NJ, August 12, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Fluorouracil Injection 50mg/mL, generic to Adrucil®. Annual market sales for Adrucil® and its generics for the twelve-month period ending June, 2021 were $22.2 million, according to IQVIA™.     Xiromed CEO, Narasimhan Mani commented, “The […]


Xiromed LLC Launches Ketoconazole Foam, 2%

August 2, 2021

Florham Park, NJ, August 2, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Ketoconazole Foam, 2%, generic to Extina®. “This is an exciting day for Xiromed as we launch our first foam product in the US market.  Xiromed is focused on expanding the range of dosage forms […]


Xiromed LLC Launches Tobramycin Vial for Injection, 1.2g

July 13, 2021

Florham Park, NJ, July 13, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Tobramycin Vial for Injection, 1.2g, generic to Nebcin®. Annual market sales for Nebcin® and its generics for the twelve month period ending April, 2021 were $16 million, according to IQVIA™.                   Xiromed CEO, […]


Xiromed LLC Launches Darifenacin ER Tablets

May 5, 2021

Florham Park, NJ, May 5, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Darifenacin Extended Release Tablets, generic to Enablex®.  “Xiromed is focused on providing quality generic products to patients in the US and the launch of Darifenacin ER Tablets is the latest example of our commitment […]


Xiromed LLC Launches Omeprazole Delayed Release Capsules, 20mg

March 25, 2021

Florham Park, NJ, March 25, 2021  Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Omeprazole Delayed Release Capsules, 20mg, generic to Prilosec®.  “Xiromed is committed to providing cost effective generic products to our customers, and the launch of Omeprazole Delayed Release Capsules is the latest example of that […]


Xiromed LLC Launches Melphalan Vial for Injection and Progesterone Capsules

March 9, 2021

Florham Park, NJ, March 9, 2021 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, announced the launch of Melphalan vial for injection 50mg, generic to Alkeran® and Progesterone capsules, 100mg and 200mg strengths, generic to Prometrium®.   “The launches of Melphalan vial for injection and Progesterone capsules are the latest examples of Xiromed’s commitment […]


Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®

November 9, 2020

Florham Park, NJ, November 9th, 2020 Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the FDA approval of Gemmily™ (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules), 1 mg/20 mcg, a therapeutically equivalent generic version of Taytulla®.  Xiromed is the first generic to Taytulla® approved in the United States.  […]


Xiromed LLC Announces the First Generic Launch of Fosfomycin Tromethamine Granules for Oral Solution, Generic to Monurol®

October 6, 2020

Xiromed LLC today announced the approval and launch of Fosfomycin Tromethamine Granules for Oral Solution, the first AA-rated generic version of Monurol® approved by the U.S. Food and Drug Administration.     Florham Park, NJ – Monurol® (fosfomycin tromethamine) granules for oral solution is a prescription antibiotic approved to treat uncomplicated urinary tract infections (UTI) […]